{
    "clinical_study": {
        "@rank": "131025", 
        "arm_group": [
            {
                "arm_group_label": "PROPOFOL", 
                "arm_group_type": "Experimental", 
                "description": "PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION"
            }, 
            {
                "arm_group_label": "METOCLOPRAMIDE", 
                "arm_group_type": "Experimental", 
                "description": "METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION"
            }, 
            {
                "arm_group_label": "PROPOFOL & METOCLOPRAMIDE", 
                "arm_group_type": "Experimental", 
                "description": "PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION"
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "arm_group_type": "Placebo Comparator", 
                "description": "SALINE INFUSION"
            }
        ], 
        "brief_summary": {
            "textblock": "Perioperative nausea and vomiting may occur in 50-80% of patients undergoing cesarean\n      section.\n\n      Metoclopramide is a well known Dopamine receptor antagonist that acts at the Chemoreceptor\n      trigger zone and  is used effectively for the prevention and treatment of nausea and\n      vomiting. Propofol can antagonize Serotonin receptors in the area postremal and is\n      associated to a reduced incidence of  postoperative nausea and vomiting. Some studies have\n      shown that propofol can prevent intraoperative nausea and vomiting during cesarean section.\n\n      The control of risk factors and the pharmacological prophylaxis of nausea and vomiting\n      reduces effectively their incidence.\n\n      In this randomized, double blind, case-control study the efficacy of propofol alone,\n      metoclopramide alone and in combination in controlling nausea and vomiting were compared. A\n      risk factor control strategy was associated to each study group."
        }, 
        "brief_title": "Prophylactic Subhypnotic Propofol for Nausea and Vomiting During for Cesarean Section Under Subarachnoid Anesthesia.", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "PREGNANCY", 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        CESAREAN SECTION WITHOUT MATERNAL OR FETAL SUFFERING\n\n        American Society of Anesthesiologists score I-II\n\n        36 TO 41 WEEK OF GESTATION\n\n        BMI < 35\n\n        HEMOGLOBIN > 10 mg/dl\n\n        NO COMPLICATIONS (GESTATIONAL DIABETES, COLESTASIS)\n\n        NO ACUTE OR CHRONIC GASTROINTESTINAL DISORDERS\n\n        NO SMOKING OR DRUG ABUSE DURING PREGNANCY\n\n        NO PREVIOUS MAJOR ABDOMINAL SURGERY\n\n        NO PREVIOUS COMPLICATED PREGNANCIES\n\n        FETAL WEIGHT > 2.5 kg\n\n        Exclusion Criteria:\n\n        EMERGENCY CESAREAN SECTION WITH MATERNAL OR FETAL SUFFERING\n\n        American Society of Anesthesiologists score III-IV-V\n\n        < 36 OR > 41 WEEK OF GESTATION\n\n        BMI > 35\n\n        HEMOGLOBIN < 10 mg/dl\n\n        COMPLICATIONS (GESTATIONAL DIABETES, COLESTASIS)\n\n        ACUTE OR CHRONIC GASTROINTESTINAL DISORDERS\n\n        SMOKING OR DRUG ABUSE DURING PREGNANCY\n\n        PREVIOUS MAJOR ABDOMINAL SURGERY\n\n        PREVIOUS COMPLICATED PREGNANCIES\n\n        FETAL WEIGHT < 2.5 kg"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781377", 
            "org_study_id": "1632/08 COET"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PROPOFOL", 
                    "PROPOFOL & METOCLOPRAMIDE"
                ], 
                "description": "PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS", 
                "intervention_name": "PROPOFOL", 
                "intervention_type": "Drug", 
                "other_name": "PROPOFOL"
            }, 
            {
                "arm_group_label": [
                    "METOCLOPRAMIDE", 
                    "PROPOFOL & METOCLOPRAMIDE"
                ], 
                "description": "METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS", 
                "intervention_name": "METOCLOPRAMIDE", 
                "intervention_type": "Drug", 
                "other_name": "METOCLOPRAMIDE"
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "description": "SALINE INFUSION", 
                "intervention_name": "PLACEBO", 
                "intervention_type": "Drug", 
                "other_name": "PLACEBO"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Propofol", 
                "Metoclopramide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NAUSEA", 
            "VOMITING", 
            "CESAREAN SECTION", 
            "PREVENTION", 
            "PROPOFOL"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chieti", 
                    "country": "Italy", 
                    "zip": "60100"
                }, 
                "name": "A.O. SS.ma Annunziata"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized Controlled Trial of Prophylactic Subhypnotic Propofol vs Metoclopramide and in Combination Therapy for the Prevention of Nausea and Vomiting During Subarachnoid Anesthesia for Cesarean Section.", 
        "overall_official": [
            {
                "affiliation": "Azienda Ospedaliera San Gerardo di Monza", 
                "last_name": "ZHIRAJR MOKINI, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Chieti", 
                "last_name": "FLAVIA PETRINI, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of Chieti", 
                "last_name": "MICHELE SCESI, M.D.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "INCIDENCE OF NAUSEA AND VOMITING", 
            "measure": "NAUSEA AND VOMITING ASSOCIATED WITH CESAREAN SECTION MEASURED WITH VAS", 
            "safety_issue": "Yes", 
            "time_frame": "FROM ANESTHESIA TO THE END OF SURGERY (AVERAGE 2 HOURS)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781377"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Ospedaliera San Gerardo di Monza", 
            "investigator_full_name": "Zhirajr Mokini", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "HEADACHE, AGITATION, SEDATION.", 
            "measure": "ADVERSE EVENTS", 
            "safety_issue": "Yes", 
            "time_frame": "FROM ANESTHESIA TO THE END OF SURGERY (AVERAGE 2 HOURS)"
        }, 
        "source": "G. d'Annunzio University", 
        "sponsors": {
            "collaborator": {
                "agency": "Azienda Ospedaliera San Gerardo di Monza", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "G. d'Annunzio University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}